USAspending awards from Department of Defense: $826,378 across 5 awards. W81K0221P0132 INTERCEPT PLATELET PATHOGEN REDUCTION SETS AT TAMC, HI; HT941024P0214 INTERCEPT PLATELET PROCESSING KITS; HT0014…
USAspending awards from Department of Health and Human Services: $228,756,330 across 5 awards. HHSO100201600009C CERUS - DEVELOPMENT AND IMPLEMENTATION OF PATHOGEN REDUCTION TECHNOLOGY (PRT). IGF::O…
The Company had the following significant customers that accounted for more than 10% of the Company’s total product revenue, during the three months ended March 31, 2026 and 2025: Three Months Ended …
The Company had the following significant customers that accounted for more than 10% of the Company’s total product revenue, during the three months ended March 31, 2026 and 2025: Three Months Ended …
Cerus Corporation Debt Obligations
Instrument
Description
Confidence
Evidence
CERS-DEBT-8595
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2012-12-31.
CERS-DEBT
Debt stack $97.4M
90%
Market cache reports total debt of $97.4M.
CERS-DEBT-8594
Warrants outstanding: 0
90%
xbrl warrant detail from xbrl 2024-12-31.
Cerus Corporation Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Cerus Corporation.
Cerus Corporation Ownership
Holder
Name
Confidence
Evidence
CERS-OWNER-BLACKROCK-INC
BlackRock, Inc.
90%
13F overlay lists BlackRock, Inc. as top holder; 168 tracked holders.
Cerus Corporation Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.